BA
MACK

BlackRock Advisors’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

BlackRock Advisors’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.14M Sell
35,623
-3,378
-9% -$144K ﹤0.01% 1789
2016
Q3 		$1.95M Buy
39,001
+25,346
+186% +$1.05M ﹤0.01% 1484
2016
Q2 		$579K Sell
13,655
-670
-5% -$36.5K ﹤0.01% 2039
2016
Q1 		$944K Sell
14,325
-16,629
-54% -$868K ﹤0.01% 1767
2015
Q4 		$1.92M Buy
30,954
+2,679
+9% +$188K ﹤0.01% 1425
2015
Q3 		$1.89M Sell
28,275
-898
-3% -$73.3K ﹤0.01% 1382
2015
Q2 		$2.84M Sell
29,173
-13,597
-32% -$1.29M ﹤0.01% 1146
2015
Q1 		$4M Sell
42,770
-937
-2% -$79.7K ﹤0.01% 1023
2014
Q4 		$3.89M Buy
43,707
+18,050
+70% +$1.31M ﹤0.01% 1034
2014
Q3 		$1.77M Buy
25,657
+20,365
+385% +$1.09M ﹤0.01% 1207
2014
Q2 		$304K Sell
5,292
-1,135
-18% -$57.6K ﹤0.01% 2380
2014
Q1 		$255K Buy
6,427
+308
+5% +$13.2K ﹤0.01% 2513
2013
Q4 		$257K Buy
6,119
+487
+9% +$14.1K ﹤0.01% 2505
2013
Q3 		$168K Buy
5,632
+254
+5% +$8.89K ﹤0.01% 2661
2013
Q2 		$285K Buy
+5,378
New +$236K ﹤0.01% 2242

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's MACK Position: Q4 2016 in Review

BlackRock Advisors reduced its Merrimack Pharmaceuticals, Inc. (MACK) stake by 8.7% in Q4 2016, selling an estimated $144K and leaving 35,623 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1789.

BlackRock Advisors first reported a position in MACK in Q2 2013 and has held it in 15 quarters since. The position peaked at $4M in Q1 2015. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

  • BlackRock Advisors held 35,623 shares of Merrimack Pharmaceuticals, Inc. worth $1.14M as of Q4 2016.
  • BlackRock Advisors sold 3,378 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $144K.
  • Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1789 holding.
  • BlackRock Advisors first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Merrimack Pharmaceuticals, Inc. position peaked at $4M in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.